Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    mglur5
Show Display Options
Rank Status Study
1 Completed PET Imaging of Brain mGluR5 Receptors Using [18F]SP203
Conditions: Healthy;   Glutamate Receptor;   mGlur5 Protein;   Excitatory Amino Acid Receptors;   Drug Kinetics;   PET Scan
Intervention: Drug: [18F]SP203
2 Completed Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain
Condition: mGluR5 Receptors
Intervention: Drug: STX107
3 Recruiting A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Conditions: Parkinson Disease;   Huntington Disease;   Autistic Spectrum Disorders;   Fragile X Syndrome;   Alzheimer Disease;   Mild Cognitive Impairment
Intervention: Drug: [18F]FPEB
4 Completed An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516
Condition: Healthy
Intervention: Drug: AZD2516
5 Terminated PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
Condition: Schizophrenia
Interventions: Radiation: PET/SPECT Scan;   Device: MRI scan
6 Completed PET Imaging of mGLuR5 With Drug Challenge
Conditions: Major Depressive Disorder;   Post-Traumatic Stress Disorder (PTSD)
Intervention: Drug: Ketamine
7 Terminated Brain Glutamate Receptors and Cocaine Dependence
Conditions: Drug Abuse;   Cocaine Dependence
8 Recruiting Examination of Glutamate and mGluR5 in Psychiatric Disorders
Conditions: Major Depressive Disorder;   Post-Traumatic Stress Disorder;   Bipolar Disorder
Interventions: Behavioral: Cognitive Testing;   Other: MRI;   Radiation: PET
9 Completed Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
Condition: Healthy
Interventions: Drug: AZD2066;   Drug: radioligand [11C] AZ12713580
10 Unknown  PET Imaging in ALS Patients
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention: Other: PET Scanning
11 Terminated ADX10059 Migraine Prevention Study
Condition: Migraine
Interventions: Drug: ADX10059;   Drug: ADX10059 Matching Placebo
12 Completed ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Condition: Gastroesophageal Reflux
Interventions: Drug: ADX10059;   Drug: ADX10059 Matching Placebo
13 Completed ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
Condition: Gastroesophageal Reflux
Interventions: Drug: ADX10059;   Drug: ADX10059 Matching Placebo
14 Completed Acamprosate: Genes Associated With Response
Condition: Alcoholism
Intervention: Drug: acamprosate
15 Not yet recruiting AFQ056 for Language Learning in Children With FXS
Condition: Fragile X Syndrome
Interventions: Drug: AFQ056;   Other: Placebo;   Other: Language Intervention
16 Terminated
Has Results
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
Conditions: Patient Diagnosed With OCD;   and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
Interventions: Drug: AFQ056;   Drug: Placebo
17 Not yet recruiting Mechanisms of Auto-immune Encephalitis
Condition: Autoimmune Encephalitis
Intervention: Other: Fundamental research
18 Active, not recruiting PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
Condition: Healthy
Interventions: Drug: ADX48621;   Radiation: [18F]FPEB

Indicates status has not been verified in more than two years